ALK and non-small cell lung carcinoma: Clinically, CA-125 has been reported to predict immunotherapy response in patients with metastatic NSCLC [19], the treatment efficacy of crizotinib and alectinib in patients with ALK-positive NSCLC [20], and the survival of patients with stable disease receiving a combination of immunotherapy, chemotherapy, and anti-angiogenesis therapy in stage IV or recurrent metastatic non-squamous NSCLC [21].